Real-world experience with clinical management of talquetamab in relapsed/refractory multiple myeloma: a qualitative study of US healthcare providers.
| Autor: | Schinke C; University of Arkansas for Medical Sciences, Little Rock, AR, USA., Dhakal B; Medical College of Wisconsin, Milwaukee, WI, USA., Mazzoni S; Cleveland Clinic, Cleveland, OH, USA., Shenoy S; University of California, San Francisco, CA, USA., Scott SA; Winship Cancer Institute, Emory University, Atlanta, GA, USA., Richards T; MD Anderson Cancer Center, Houston, TX, USA., Le HH; Johnson & Johnson Innovative Medicine, Horsham, PA, USA., DeBrosse A; Avalere Health, New York, NY, USA., Okorozo P; Avalere Health, New York, NY, USA., McDowell R; Avalere Health, New York, NY, USA., Patel S; Johnson & Johnson Innovative Medicine, Horsham, PA, USA., Bunn J; Johnson & Johnson Innovative Medicine, Horsham, PA, USA., Hawks K; Johnson & Johnson Innovative Medicine, Horsham, PA, USA., Zhang X; Johnson & Johnson Innovative Medicine, Horsham, PA, USA., Rodriguez C; Mount Sinai School of Medicine, New York, NY, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Current medical research and opinion [Curr Med Res Opin] 2024 Oct; Vol. 40 (10), pp. 1705-1711. Date of Electronic Publication: 2024 Aug 23. |
| DOI: | 10.1080/03007995.2024.2387183 |
| Abstrakt: | Objective: Talquetamab is the first-in-class GPRC5DxCD3 bispecific antibody for relapsed/refractory multiple myeloma. Given limited real-world data, this study was conducted with US healthcare providers (HCPs) to understand real-world talquetamab dosing and symptom management. Methods: In February/March 2024, individual in-depth interviews (IDIs; n = 10) were conducted with HCPs administering talquetamab in real-world settings. A subsequent expert panel ( n = 6) further discussed current practices. Results: The IDIs reported a variety of settings for step-up dosing (SUD), including inpatient ( n = 5), outpatient ( n = 3), and hybrid models ( n = 2), with a trend toward shorter SUD length to reduce healthcare resource utilization. Most HCPs used a biweekly (Q2W) schedule in SUD ( n = 7) and treatment phases ( n = 8). Six participants explored reducing dose frequency to every 4 weeks (Q4W) in patients following positive disease response to treatment, considering patient convenience and relieving GPRC5D-related symptoms. Panelists recommended symptom management and prophylactic strategies, such as dexamethasone and nystatin mouthwash or zinc and vitamin B complex for oral symptoms, and topical steroids and cosmetic products for skin and nail symptoms. Conclusion: This study outlines current real-world practices for talquetamab. Findings indicate variation in the SUD care setting. The 0.8 mg/kg Q2W dosing schedule was most common, although switching to Q4W is a real-world symptom management strategy for some patients with responses to therapy. GPRC5D-related symptom management approaches are evolving; prophylactic use of dexamethasone and nystatin mouthwash or zinc and vitamin B complex may be effective strategies to alleviate oral symptoms. Further real-world evidence is needed to inform optimal dosing schedules while mitigating symptom impact. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|